Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial.
OBJECTIVE
To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis.


METHODS
In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects.


RESULTS
Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial.


CONCLUSIONS
Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.
Cho
Se Haeng
SH
Yonsei Medical Clinic, Seoul, Korea.
Jung
Young Bok
YB
Seong
Sang Cheol
SC
Park
Hyung Bin
HB
Byun
Ki Yong
KY
Lee
Dong Chul
DC
Song
Eun Kyoo
EK
Son
Jung Hwan
JH
D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D049872:Bivalvia / Q000737:chemistry; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000009:adverse effects / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000188:drug therapy*; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D012449:Safety; D014020:Tissue Extracts / Q000627:therapeutic use; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015525:Fatty Acids, Omega-3; D020024:Leukotriene Antagonists; D008055:Lipids; D016859:Lipoxygenase Inhibitors; D014020:Tissue Extracts; C418997:lyprinol